#ESMO26 🧬 PRABITAS | Phase III
👥 970 pts | Refractory mCRC
💊 FTD/TPI + BEV: biweekly vs conventional
⏳ mOS: 11.3 vs 10.3 mo
✅ Non-inferior OS (HR 0.93; p<0.0001)
📈 mPFS: 3.9 vs 3.9 mo
⚠️ G≥3 neutropenia: 13% vs 39%
💉 G-CSF use: 3% vs 13%
🚀 Similar efficacy, less toxicity!
@OncoAlert